The FDA Just Banned 17 Peptide Treatments

The agency banned peptides from certain pharmacies, but others blazed past new regulations.

30-Second Takeaway

The FDA banned compounding pharmacies from selling certain peptide therapies. While unrestricted vendors may continue selling these treatments, this route is risky. Here’s what to do if your protocol was impacted by the new regulations.

Peptide therapy has recently gone mainstream thanks to popular peptides like semaglutide (Ozempic) and tirzepatide (Mounjaro). But bodybuilders, longevity buffs, health podcasters, and biohackers are reeling after the FDA recently banned 17 other popular peptides.

Peptides are a chain of amino acids that your body uses to perform essential functions (1). When injected or ingested, they can deliver longevity benefits including weight loss, muscle gain, brain health, libido, hormone management, and more.

But not all peptides are as well researched—which is one of the primary reasons why the FDA recently released new regulations limiting the sale of certain prescription peptide treatments. (There are still black market peptide pushers that sell the now-banned peptides without a valid prescription—but this route is risky and not recommended).

Peptides that are well-studied and have a generic form were deemed okay by the FDA. However, peptides with little clinical research were on the chopping block due to concerns of impurities and dangerous side effects linked to compounded treatments.

Unlike regular pharmacies that sell pre-manufactured drugs, compounding pharmacies can put prescribed drugs into custom topical treatments, injectables, flavored liquids, and more at specified doses.

However, compounded peptides run the risk of variability between treatments. Hence, the FDA cracking down on compounding pharmacies mixing peptides that the agency deems under-researched or dangerous.

While the ban is immediate, compounding pharmacies can still run through their current stock of the now-regulated peptides.

Curious if your go-to peptide therapy is on the list? The following peptides were affected by the FDA ban. Plus, alternatives for treatment if your protocol was impacted.

Peptides Impacted by FDA Restrictions

AOD-9604

AOD-9604 is beloved by bodybuilders for its purported ability to speed up metabolism, burn stubborn fat, and amp muscle growth by boosting human growth hormone and curbing insulin resistance (2).

Human growth hormone, or HGH, is released by the pituitary gland to promote height in puberty, muscle growth, and bone strength (3). As you age, your HGH levels fall (4)—which makes AOD-9604 popular among people looking to boost muscle

Why it was included in the FDA ban

AOD-9604 was cited as having a “risk for immunogenicity (the ability to trigger a negative immune reaction), peptide-related impurities, and limited safety-related information.”

BPC-157

BPC-157, aka the “magic peptide,” is a biohacking fan-favorite for its potential to improve brain function, boost gym gains, improve joint pain, and heal gut inflammation (5, 6, 7). Animal studies suggest this peptide may also promote angiogenesis—the process in which your body makes more blood vessels (8).

Why it was included in the FDA ban

The FDA cites “risk for immunogenicity, peptide-related impurities, and limited safety-related information” as reasons for the BPC-157 ban.

BPC-157 is still available as an oral pill. BPC-157 is one of the only peptides that can survive the acidic environment in your stomach (9), so oral treatment is likely very effective.

Expert Swaps:

Pentosan polysulfate is an injectable peptide that has been shown to improve osteoarthritis and other joint pain (10). This peptide may work as an alternative if you primarily take BPC-157 for joint health.

Larazotide is a peptide that may reduce gut permeability  by strengthening your gut lining (11). Ask your doctor about using this peptide as a replacement if you take BPC-157 to promote gut health.

BODY RE-COMP

Yes, Testosterone Injections Actually Build Muscle. Here’s How.

CJC-1295

At a glance, CJC-1295 seems like an all-around longevity-supporting peptide, touting better sleep, increased muscle mass and weight loss, boosted cognitive and immune function, and slowed skin aging (12, 13, 14) in animal studies.

Why it was included in the FDA ban

According to the FDA, CJC-1295 carries a risk for increased heart rate and cardiac events. Plus, compounded CJC-1295 runs the risk of peptide impurities and harmful immune responses, according to the agency.

Expert Swap: 

Like CJC-1295, Sermorelin also promotes healthy body composition by increasing growth hormone (15).

DIHEXA

DIHEXA is a blood-brain barrier-penetrating peptide commonly used by people concerned about their risk for degenerative diseases like Alzheimer’s, dementia, and Parkinson’s (16). Users claim that DIHEXA increases mental stamina, improves problem-solving skills, manages depression, and boosts memory.

Why it was included in the FDA ban

While animal studies suggest that DIHEXA may tout these brain benefits (17), the FDA says it “has not identified any human exposure data.” Meaning: The safety and efficacy of DIHEXA for humans is still up in the air.

Expert Swaps: 

Cerebrolysin is a brain recovery peptide that has shown promise in staving off neurodegenerative diseases like Alzheimer’s (18). (Fibroblast Growth Factor) may improve memory (19).

DSIP

If you  can’t get to sleep, you may have stumbled across DSIP in a biohacking subreddit. DSIP is thought to increase production of GABA (20)—a neurotransmitter that slows brain activity, promotes relaxation, and increases time spent in deep sleep. Research shows that increasing GABA levels may help improve insomnia (21).

Why it was included in the FDA ban

Research on DSIP in humans is still lacking, per the FDA. However, you can purchase GABA supplements at your local health foods store.

Epitalon

Epitalon is a synthetic version of the natural peptide Epithalamin, which is produced by the pineal gland (22). Epitalon may regulate the pineal gland, which can bump your production of sleep-supporting hormones serotonin and melatonin.

Some research also suggests that Epitalon can also lengthen your telomeres—the caps at the end of your chromosomes that shorten with age (23). Telomere length is a key marker used to calculate cellular aging, and maintaining longer telomeres is thought to slow down cellular aging.

Why it was included in the FDA ban

Compounded Epitalon was banned because of a potential for peptide impurities and immune reactions. Epitalon is still available in pill form.

AGE WELL

Metformin Could Benefit Your Health, Even If You Don’t Have Diabetes
What is NAD+ (NAD Plus) and Why Is it Important?

GHK-Cu

GHK-Cu, or copper peptides, are a combination of tripeptide Glycyl-L-Histidyl-L-Lysine and copper ions. Research suggests that this peptide may stimulate collagen production—a protein that helps maintain skin elasticity and firmness—which has boosted its popularity in anti-aging skincare treatments (24). GHK-Cu is also thought to be a powerful antioxidant, which may support wound healing, reduce inflammation, and enhance skin regeneration.

Why it was included in the FDA ban

Injectable GHK-Cu was banned because of a high risk for immune reactions and impurities during the compounding process. GHK-Cu is still available in topical skincare products.

Ipamorelin

Ipamorelin is a growth hormone-releasing peptide (GHRP) commonly used to stimulate muscle growth and improve post-workout recovery and metabolism (25).

Why it was included in the FDA ban

In the FDA release, the agency cites a study in which serious adverse events including death occurred when patients were given ipamorelin through an IV.

KPV

KPV—a relatively new anti-inflammatory peptide—is sought out for its ability to speed up healing, curb infection, and axe chronic inflammation (26). For example, one Reddit user claims that KPV treatment helped curb symptoms of their mast cell disease and histamine reactions.

Why it was included in the FDA ban

There have been no human trials on KPV to date.

LL-37

LL-37 is a naturally occurring antimicrobial peptide which some research suggests might help your body fight off harmful bacteria, viruses, and fungi (27). This peptide has also been studied as a potential anti-inflammatory treatment, and research suggests it may show  promise in treating skin conditions like rosacea (27).

Why it was included in the FDA ban

Nonclinical research findings suggest that LL-37 could negatively impact male fertility. Plus, LL-37 could be protumorigenic—meaning it could cause tumors to develop—in some tissues.

Melanotan II

Melanotan II mimics the hormone alpha-melanocyte-stimulating hormone (α-MSH), which controls skin pigmentation (28). People gravitate towards this peptide to deepen their tan.

Why it was included in the FDA ban

Melanotan II was banned for reported adverse effects like melanoma skin cancers, posterior reversible encephalopathy syndrome (a seizure and headache disorder), sympathomimetic toxidrome (symptoms of poisoning), and priapism (dangerous, prolonged erections).

MOTS-C

MOTS-C may boost metabolism and promote muscle repair. This peptide has also shown promise in boosting mitochondrial function and cellular energy (29).

Why it was included in the FDA ban

Research has not yet proven MOTS-C to deliver the above benefits. However, the agency cites initial findings that show that it may be used for future treatment of age-related conditions and metabolic disorders.

Ibutamoren

Ibutamoren, often called MK-677, is a selective growth hormone secretagogue receptor (GHSR) agonist, meaning it stimulates the release of the muscle and bone-supporting growth hormone that your body naturally makes (30).

Why it was included in the FDA ban

The FDA cites significant safety “risks due to the potential for congestive heart failure in certain patients” seen in a clinical trial that was terminated.

Selank

Selank is an anti-anxiety and nootropic (brain-boosting) peptide being researched for its ability to balance neurotransmitters like serotonin, dopamine, and norepinephrine (31). These neurotransmitters play a role in regulating mood and appetite.

Why it was included in the FDA ban

Selank has a high risk of immune reactions and impurities during the compounding process, according to the agency’s press release.

Semax

Semax is derived from adrenocorticotropic hormone (ACTH), which regulates cortisol and androgen production. Studies suggest that Semax may boost memory, attention, and learning by modulating neurotransmitter activity in the brain (32). Plus, this peptide has also shown neuroprotective properties by lowering oxidative stress and improving overall brain health in animal studies (33).

Why it was included in the FDA ban

Semax has a high risk of immune reactions and impurities during the compounding process.

Expert Swap:

PE 22-28 is a peptide commonly used to improve depression, boost memory, and prevent stroke (34). Discuss this peptide with your prescriber if you take Semax.

Thymosin Beta 4

Thymosin Beta 4 is a naturally occurring peptide that studies suggest may help with tissue repair and regeneration (35). Initial research has found that Thymosin Beta 4 has anti-inflammatory properties and may boost heart health (35).

Why it was included in the FDA ban

The agency cited a lack of human trials and the risk for immune reactions and peptide impurities with injectable Thymosin Beta 4. The pill version of the peptide wasn’t impacted by the ban.

Thymosin Alpha 1

Thymosin Alpha 1 is a synthetic version of the thymic peptide that has shown promise in boosting immune health (36). Some research shows that Thymosin Alpha 1 may increase your body’s natural T-cell production, which helps you fight infections and diseases (36).

Why it was included in the FDA ban

Injectable Thymosin Alpha 1 may be linked to immune reactions.

What If I’m Already Taking a Banned Peptide?

If you’re already taking one of the peptides impacted by the new FDA regulations, take these steps to preserve your peptide therapy results.

1. Talk to your provider about alternatives

The FDA hasn’t banned all peptides, and many of the regulations only cover compounded peptide treatments. You may be able to  continue treatment with a few tweaks in the administration method.

For example, many oral versions of peptides (like BPC-157 and Thymosin Beta 4) are not banned—it’s just the injectables. Talk to your prescriber about a replacement oral version or injectable peptide that offers similar benefits.

2. Be wary of compounds from unregulated pharmacies

While the FDA has banned compounding pharmacies from making certain peptides, there are other pharmacies—dubbed ‘unregulated pharmacies’—that are not regulated by the government. These pharmacies may still manufacture banned peptides—but be wary of quality and safety if you are intent on going this route.

Products from some unregulated pharmacies may be tainted with heavy metals like mercury.

If you decide to get a peptide prescription through an unregulated pharmacy, ensure it has favorable reviews and a recent certificate of authenticity (COA).

You can also ask the pharmacy if you can send the peptide to a lab to verify the contents. If they give you hesitancy with that, then that’s a red flag

  1. Forbes, et al (2023) Biochemistry, Peptide
  2. Ng, et al (2000) Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
  3. Brinkman, et al (2023) Physiology, Growth Hormone
  4. Garcia, et al (2019) Growth Hormone in Aging
  5. Vukojevic, et al (2022) Pentadecapeptide BPC 157 and the central nervous system
  6. Lee, et al (2021) Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
  7. Sikiric, et al (2016) Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications
  8. Hsieh, et al (2017) Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
  9. Seiwerth, et al (2021) Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
  10. Liu, et al (2023) The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot study
  11. ScienceDirect (2022) Larazotide
  12. Alba, et al (2006) Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
  13. Teichman, et al (2006) Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
  14. Gautam, et al (2009) Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth
  15. Walker, et al (2006) Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?
  16. Sun, et al (2021) AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway
  17. Weiss, et al (2021) Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies
  18. Gauthier, et al (2015) Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials
  19. Zellinger, et al (2014) Impact of the Neural Cell Adhesion Molecule-Derived Peptide FGL on Seizure Progression and Cellular Alterations in the Mouse Kindling Model
  20. Tukhovskaya, et al (2021) Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke
  21. Hepsomali, et al (2020) Effects of Oral Gamma-Aminobutyric Acid (GABA) Administration on Stress and Sleep in Humans: A Systematic Review
  22. Khavinson, et al (2020) AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism
  23. Shammas (2012) Telomeres, lifestyle, cancer, and aging
  24. Pickart, et al (2018) Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
  25. Sinha, et al (2020) Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
  26. Xiao, et al (2017) Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
  27. Reinholz, et al (2012) Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease
  28. Gilhooley, et al (2021) Melanotan II User Experience: A Qualitative Study of Online Discussion Forums
  29. Mohtashami, et al (2022) MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases
  30. Liu, et al (2021) Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren
  31. Volkova, et al (2016) Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
  32. Glazova, et al (2021) Semax, synthetic ACTH(4–10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats
  33. Sudarkina, et al (2021) Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia–Reperfusion
  34. Djillani, et al (2017) Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
  35. Xing, et al (2021) Progress on the Function and Application of Thymosin β4
  36. Dominari, et al (2020) Thymosin alpha 1: A comprehensive review of the literature

Read more : https://honehealth.com/edge/fda-peptide-ban/

CSIR launches Africa’s first microencapsulation facility to boost local health, cosmetic innovation

The Council for Scientific and Industrial Research (CSIR) has launched a new facility in Pretoria that will, for the first time, help local manufacturers develop their own microencapsulation technologies on home soil. Microencapsulation is a way of protecting sensitive components in health and cosmetic products, such as probiotics and essential oils, thereby improving shelf-life and efficacy.

The new Supercritical Carbon Dioxide Encapsulation Facility formally welcomed industry partners and government officials on 17 October 2025, following an investment of R25.9 million by the Department of Science, Technology and Innovation (DSTI).

Facility
The CSIR’s new Supercritical Carbon Dioxide Encapsulation Facility formally welcomed industry partners and government officials on 17 October 2025, following an investment of R25.9 million by the Department of Science, Technology and Innovation. The facility brings key microencapsulation technology, which protects sensitive ingredients in probiotics, essential oils and other health and cosmetic products, to Africa for the first time.
The new facility will boost South Africa’s innovation and manufacturing sectors, enabling high-value, sustainable production, while supporting localisation, job creation and Africa’s growing bio-based economy.
Speaking at the launch event, CSIR Chief Executive Officer Dr Thulani Dlamini, said the facility “opens the door for local researchers, entrepreneurs and manufacturers to test, refine and scale their innovations right here at home, reducing reliance on international facilities and accelerating the path from laboratory to market.”
He was referring to innovations in product formulations that use supercritical carbon dioxide (CO2) to create microcapsules that protect delicate ingredients. CO2 used in this microencapsulation process is not in gas or liquid form, but rather somewhere in between, in the so-called supercritical fluid state of matter.
The CSIR’s Dr Philip Labuschagne said the process works by first dissolving supercritical carbon dioxide into a mixture of active ingredients and coating materials. The solution is then rapidly sprayed through a nozzle, releasing CO2 for later reuse, producing a fine powder of microcapsules (the active ingredient, encapsulated within the coating material).
“In your final powder product, you get tiny particle sizes of between 10 and 100 microns, and your active ingredient, whether it is a vitamin or even an oily liquid, is then dispersed within the particles,” he said.
 particles spherical particles particles
Scanning electron microscope images of microparticles produced using supercritical carbon dioxide. At the CSIR’s new facility, local cosmetic and health companies can now develop their own new product formulations to protect sensitive ingredients, thereby improving shelf-life, efficacy and stability. 
Labuschagne said products that could benefit from a supercritical CO2-based encapsulation technology include nutritional health supplements that are sensitive to oxygen, moisture, heat or stomach acid, such as probiotics, certain phytochemicals and volatile essential oils or plant extracts that evaporate easily.
Adelia Pimentel, executive director of the Cosmetic, Toiletry and Fragrance Association of South Africa, said during the launch that her industry body foresees several benefits of microencapsulation for local businesses and consumers, including better product stability, efficacy and shelf-life.
“The specific types of companies that will benefit from this particular facility would be anti-ageing and skincare brands,” said Pimentel, adding that the technology will boost innovation in fragrance, personal care, sensitive skin, make-up and other premium products.
“And then, of course, the sustainability and safety factor is always something that is important,” she said.
Labuschagne explained that the microencapsulation process requires no toxic organic solvents and takes place at relatively low temperatures, like 30 degrees Celsius. “It’s really a green and safe process, and most of the carbon dioxide, which is sourced and recovered from waste processes, is recycled back into the system,” he said.
facility Facility
The CSIR’s Dr Philip Labuschagne (right) and the CEO of local gut health supplement business Velobiotics, Dr Chomba Chuma, discuss the microencapsulation of probiotics at the CSIR’s new Supercritical Carbon Dioxide Encapsulation Facility. 
Local gut health supplement business Velobiotics already uses CSIR’s facilities to produce microencapsulated formulations of probiotics. The process ensures that their products can survive the highly acidic stomach environment on their way to the intestines, where they are active.
CSIR researchers used a scanning electron microscope to verify the success of the microencapsulation process and checked that the final powder product can withstand the level of acidity (a pH of about two) encountered in the stomach.
“The CSIR is one of the biggest stakeholders we have, because this facility is the only one available in Africa,” said Velobiotics CEO, Dr Chomba Chuma, who now sees several of his company’s gut health products on major retailers’ shelves.
In his view, the new facility is a “beacon of African excellence” and a “launchpad for African biotech.”
“I want to thank the CSIR for believing in innovation, and the DSTI for supporting it,” said Chuma. He also said that without the CSIR’s scientific support, scaling his business would have been unaffordable.
facility
Supercritical carbon dioxide encapsulation technology yields a fine powder of microencapsulated product. First, supercritical carbon dioxide is dissolved in a mixture of active ingredients and coating materials. The solution is then rapidly sprayed through a nozzle, releasing the carbon dioxide for later reuse. Products that could benefit from this microencapsulation technology include probiotics or nutritional supplements that could be vulnerable to stomach acid, and volatile essential oils or plant extracts that evaporate easily. 
DSTI Director-General Dr Mlungisi Cele also addressed the media and industry representatives. “We see the launch of this facility as an important step in South Africa’s development of new high-tech industries to support manufacturing, which remains a key priority for our economy,” he said.
Nontombi Maseko, Director of Innovation and Technology at the Department of Trade and Industry, added that this facility will help anchor small to medium enterprises, enabling them to build from the ground up. She said her department offers incentives to further support such businesses in developing and commercialising new technologies.
-ENDS-
Issued by CSIR
For enquiries, contact:
Media enquiries:
Phetolo Phatsibi
Media practitioner
pp[email protected] or 081 396 8871
About the CSIR:
The CSIR, an entity of the Ministry of Science, Technology and Innovation, is one of Africa’s leading organisations in scientific and technology research, development and implementation. Constituted by an Act of Parliament in 1945 as a science council, the CSIR undertakes directed and multidisciplinary research and technological innovation, as well as industrial and scientific development, to improve the quality of life of all South Africans.
This year, the CSIR celebrates 80 years of touching lives through innovation. For more information, visit www.csir.co.za

Call to avoid buying fake versions of Ozempic and Mounjaro

Monday, November 11, 2024

The South African Health Products Regulatory Authority (SAHPRA) has expressed concern at the increasing presence of counterfeit Glucagon-like Peptide (GLP-1) products, such as Ozempic, on the local market.

According to SAHPRA, GLP-1-containing products, like Ozempic, which help lower blood sugar levels and promote weight loss, are being made available to the public through websites, social media, and other informal channels.

“These pose a health risk to the public. SAHPRA cautions the public to not purchase and/or consume such products as their safety, efficacy, and quality have not been assessed.”

SAHPRA has reported an increase in suspected counterfeit Ozempic, chemically known as semaglutide, which is one of the registered products containing GLP-1 agonists from Novo Nordisk.

According to the watchdog, Ozempic in South Africa is registered under two presentations of pre-filled injectable pens, namely 0.25 mg and 0.5 mg/dose pen and 1 mg/dose pen.

“Ozempic is registered in South Africa for the treatment of adults with type 2 diabetes to reduce blood sugar levels for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.”

It is also approved to reduce the risk of major cardiovascular events, such as heart attack, stroke, or death, in adults with type 2 diabetes who have known heart disease.

“Ozempic is not registered in South Africa for weight management,” said the authority.

Mounjaro (tirzepatide), developed by Eli Lilly and Company, is also gaining attention in South Africa. It is available in pre-filled pens that come in a single dosage, containing either 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg in a 0.5 ml solution for injection.

Mounjaro is indicated for treating type 2 diabetes mellitus but has not yet been imported into and placed on the market in South Africa through Eli Lilly and Company distribution channels.

Just like Ozempic, the watchdog stated that Mounjaro is not approved in South Africa for weight management.

“The complexity of compounding GLP-1 agonists, which are sterile medicines containing complex active substances poses a public health and safety risk.

“The risk associated with compounded medicines containing GLP-1 agonists are posed by the absence of the evaluation of these medicines by SAHPRA and the unknown nature and safety of ingredients used in compounding.”

Compounded products that claim to contain semaglutide have not been verified or evaluated by SAHPRA to determine if the active pharmaceutical ingredient is identical to the registered one, as required by the Medicines Act.

“Therefore, it maybe substandard and pose a risk to those using them,” said SAHPRA, adding  that the medicine using an active ingredient that is not contained in a product registered with SAHPRA is illegal in terms of the requirements of the Medicines and Related Substances Act.

“The public is urged to purchase only SAHPRA-registered products containing GLP-1 agonists, considering these risks.”

According to Section 29 of the Medicines and Related Substances Act, a person who commits an offence will be held criminally liable, and applicable penalties will be enforced.

SAHPRA CEO, Dr Boitumelo Semete-Makokotlela, stressed that safeguarding the well-being of the South African public remains a primary concern for the regulatory authority.

“SAHPRA is monitoring the supply chain as well as the online platforms for unregistered, substandard, and falsified medicines containing or claiming to contain semaglutide. We are also investigating any contraventions relating to the Medicines and Related Substances,” said Dr Semete-Makokotlela.

The public is urged to report any suspected products falsely claiming to be sold as Ozempic or Mounjaro.

Citizens are urged to report through these whistle-blower platforms, SAHPRA’s 24-hour hotline 0800 204 307, or via https://bit.ly/3nrku5t. – SAnews.gov.za

More reading : https://www.sanews.gov.za/south-africa/call-avoid-buying-fake-versions-ozempic-and-mounjaro

Free Delivery

Free delivery nationwide in South Africa for qualifying orders

Highly qualified experienced Whatsapp support

Our support centers are manned by the most knowledgeable and experienced peptide users and professionals in the country.

Secure Checkout

100% Protected payment method facilitated by PayFlex

Copyright © 2026 Peptides Africa. All Rights Reserved.

Our Payment Partners :

Add to cart